- Report
- September 2026
- 191 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- November 2025
- 188 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- December 2025
- 150 Pages
Global
From €4409EUR$4,850USD£3,790GBP
- Report
- September 2026
- 185 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 198 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 196 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 181 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 186 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- July 2026
- 295 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- May 2026
- 400 Pages
Global
From €4499EUR$4,949USD£3,868GBP
- Report
- April 2026
- 150 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- April 2026
- 99 Pages
Global
From €3500EUR$4,125USD£3,115GBP
- Report
- August 2024
- 80 Pages
Japan
From €3181EUR$3,500USD£2,735GBP
- Report
- May 2024
- 137 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- August 2026
- 160 Pages
China
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- October 2022
- 27 Pages
Global
€11135EUR$12,250USD£9,574GBP
- Report
- September 2021
- 40 Pages
China
From €2363EUR$2,600USD£2,032GBP
- Report
- September 2026
- 50 Pages
Global
From €2409EUR$2,650USD£2,071GBP
- Report
- September 2026
- 50 Pages
Global
From €2409EUR$2,650USD£2,071GBP

Mesalazine is a drug used to treat gastrointestinal diseases such as ulcerative colitis and Crohn's disease. It is a type of aminosalicylate, which works by reducing inflammation in the digestive tract. It is available in both oral and rectal forms, and is often used in combination with other medications. Common side effects include nausea, headache, and abdominal pain.
Mesalazine is a widely used drug in the gastrointestinal market, and is often prescribed as a first-line treatment for inflammatory bowel diseases. It is generally well-tolerated and has a low risk of serious side effects. It is also used to treat other conditions such as pouchitis and microscopic colitis.
The mesalazine market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, AstraZeneca, and Novartis. Show Less Read more